MATTERHORN: Durvalumab plus FLOT significantly improves event-free survival in resectable gastric/GEJ adenocarcinoma

A new standard may be emerging for the perioperative treatment of resectable gastric and gastroesophageal junction (GEJ) adenocarcinoma. Results from the phase 3 multinational, double-blind, randomised MATTERHORN trial showed that adding the programmed cell death-ligand 1(PD-L1) inhibitor durvalumab to the standard FLOT regimen significantly improves event-free survival (EFS) in this high-risk population, without increasing toxicity or compromising surgical feasibility. Dr Yelena Janjigian (Memorial Sloan Kettering Cancer Center, NY, USA) presented the late-breaking results of the MATTERHORN study (NCT04592913), which were simultaneously published in the New England Journal of Medicine [1,2]. A total of 948 participants with resectable gastric or GEJ adenocarcinoma were enrolled and randomised 1:1 to receive either durvalumab (1,500 mg every 4 weeks) or placebo, combined with 4 cycl...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 30 July 202530 July 2025